These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 10383534)

  • 21. Acid control and regression of Barrett's esophagus: is the glass half full or half empty?
    Castell DO; Katz PO
    Am J Gastroenterol; 1997 Dec; 92(12):2329-30. PubMed ID: 9399786
    [No Abstract]   [Full Text] [Related]  

  • 22. Evidence that proton-pump inhibitor therapy induces the symptoms it is used to treat.
    McColl KE; Gillen D
    Gastroenterology; 2009 Jul; 137(1):20-2. PubMed ID: 19482105
    [No Abstract]   [Full Text] [Related]  

  • 23. [Influence of CYP2C19 polymorphism and Helicobacter pylori status on the antisecretory effect of omeprazole in gastroesophageal reflux disease].
    Sohn YH; Lee WS; Park CH; Joo YE; Kim HS; Choi SK; Rew JS; Kim SJ
    Korean J Gastroenterol; 2006 Sep; 48(3):162-71. PubMed ID: 17047431
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of erosive oesophagitis with omeprazole: a comparison with different delivery system.
    Lu CL; Chen TS; Chen CY; Chang FY; Kang LJ; Lee SD
    Dig Liver Dis; 2001 Nov; 33(8):731. PubMed ID: 11785721
    [No Abstract]   [Full Text] [Related]  

  • 25. Gastric Hyperplastic Polyps Associated with Proton Pump Inhibitor Use in a Case without a History of Helicobacter pylori Infection.
    Miyamoto S; Kato M; Matsuda K; Abiko S; Tsuda M; Mizushima T; Yamamoto K; Ono S; Kudo T; Shimizu Y; Hatanaka KC; Tsunematsu I; Sakamoto N
    Intern Med; 2017; 56(14):1825-1829. PubMed ID: 28717077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Helicobacter pylori infection and antisecretory efficacy of proton-pump inhibitors in gastroesophageal reflux disease: a liaison dangereuse or an innocent interplay?
    Parente FR; Bargiggia SA; Anderloni A
    Scand J Gastroenterol; 2006 Oct; 41(10):1121-5. PubMed ID: 16990195
    [No Abstract]   [Full Text] [Related]  

  • 27. Treatment with proton pump inhibitors induces tolerance to histamine-2 receptor antagonists in Helicobacter pylori-negative patients.
    Qvigstad G; Arnestad JS; Brenna E; Waldum HL
    Scand J Gastroenterol; 1998 Dec; 33(12):1244-8. PubMed ID: 9930386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The influence of Helicobacter pylori on oesophageal acid exposure in GERD during acid suppressive therapy.
    Peters FT; Kuipers EJ; Ganesh S; Sluiter WJ; Klinkenberg-Knol EC; Lamers CB; Kleibeuker JH
    Aliment Pharmacol Ther; 1999 Jul; 13(7):921-6. PubMed ID: 10383527
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Helicobacter pylori and omeprazole therapy in GERD.
    Kuipers EJ; Schenk BE; Klinkenberg-Knol EC; Meuwissen SG
    Am J Gastroenterol; 1999 Nov; 94(11):3378-9. PubMed ID: 10566757
    [No Abstract]   [Full Text] [Related]  

  • 30. Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.
    Horn J
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():11-9. PubMed ID: 15496214
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease.
    Castell D; Bagin R; Goldlust B; Major J; Hepburn B
    Aliment Pharmacol Ther; 2005 Jun; 21(12):1467-74. PubMed ID: 15948814
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease.
    Janczewska I; Sagar M; Sjöstedt S; Hammarlund B; Iwarzon M; Seensalu R
    Scand J Gastroenterol; 1998 Dec; 33(12):1239-43. PubMed ID: 9930385
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drugs, bugs, and esophageal pH profiles.
    Robinson M
    Yale J Biol Med; 1999; 72(2-3):169-72. PubMed ID: 10780578
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early epigastric pain after PPI administration: exacerbation of Helicobacter pylori corpus gastritis?
    Di Mario F; Ingegnoli A; Dal Bò N; Cavestro GM; Moussa AM; Cavallaro LG; Aragona G; Iori V; Pilotto A; Franzè A; Rugge M
    Helicobacter; 2004 Feb; 9(1):92-4. PubMed ID: 15156910
    [No Abstract]   [Full Text] [Related]  

  • 35. Rationale for a Helicobacter pylori Test and Treatment Strategy in Gastroesophageal Reflux Disease.
    Vakil N
    Gastroenterol Clin North Am; 2015 Sep; 44(3):661-6. PubMed ID: 26314675
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH.
    Kirchheiner J; Glatt S; Fuhr U; Klotz U; Meineke I; Seufferlein T; Brockmöller J
    Eur J Clin Pharmacol; 2009 Jan; 65(1):19-31. PubMed ID: 18925391
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term safety and efficacy of omeprazole in gastro-oesophageal reflux disease.
    Armstrong D
    Lancet; 2000 Aug; 356(9230):610-2. PubMed ID: 10968429
    [No Abstract]   [Full Text] [Related]  

  • 38. Helicobacter pylori seropositivity predicts outcomes of acid suppression therapy for laryngopharyngeal reflux symptoms.
    Oridate N; Takeda H; Yamamoto J; Asaka M; Mesuda Y; Nishizawa N; Mori M; Furuta Y; Fukuda S
    Laryngoscope; 2006 Apr; 116(4):547-53. PubMed ID: 16585857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pharma clinics medication of the month. Esomeprazole].
    Louis E
    Rev Med Liege; 2002 Sep; 57(9):610-2. PubMed ID: 12440351
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Omeprazole: Helicobacter pylori makes thee greater yet.
    Pantoflickova D; Blum AL; Bercik P
    Gut; 1999 Apr; 44(4):448-9. PubMed ID: 10075943
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.